Home › NDC Lookup › J-codes › J2425
J2425

J2425 – Injection, palifermin, 50 micrograms · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 2 NDCs crosswalked per 50 MCG $38.690/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J2425 summary

J2425 is a HCPCS Level II J-code used to bill palifermin, 50 micrograms, billed per 50 MCG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J2425: Kepivance

Code J2425 Billing unit 50 MCG Payment limit $38.690/unit NDC-Crosswalk 2 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ2425
DescriptorInjection, palifermin, 50 micrograms
Billing unit50 MCG
Payment limit / unit$38.690
Est. ASP / unit$36.500 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20

💊 About Palifermin DRUG GUIDE

Kepivance (palifermin) is used to decrease how often and how long severe oral mucositis — painful sores in the mouth and throat — occurs in patients with hematologic malignancies (blood cancers such as lymphoma, leukemia, or multiple myeloma) who are receiving high-dose, cell-damaging (myelotoxic) therapy before an autologous hematopoietic stem cell transplant (a transplant using the patient's own stem cells).Kepivance is specifically indicated when the preparative chemotherapy or radiation regimen is expected to cause severe mucositis in most patients.

It is not recommended for use with a high-dose melphalan conditioning regimen, and it was not found to be effective in the setting of allogeneic stem cell transplant (using a donor's cells).

Its safety and effectiveness have not been established for patients with non-blood cancers (non-hematologic malignancies).

Read the full Palifermin drug guide →
Clinical overview from our editorial drug guide for Palifermin. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$38.690
Est. ASP / unit
$36.500 est.
Est. after 2% sequester
$37.916
HCPCS dosage
50 MCG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, palifermin, 50 micrograms
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2006-01-01
Date added2006-01-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J2425 = 50 mcg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J2425 WITH EST. MEDICARE PAY

2 NDCs map to J2425. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($38.690/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
66658-0113-03 KEPIVANCE palifermin 5.16 mg/1.2mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION Swedish 3 VIAL, SINGLE-USE in 1 CARTON (66658-113-... 5.16 mg/1.2mL 310 $11,993.90 — ● Active CMS ASP
66658-0113-06 Kepivance Swedish — — 620 $23,987.80 — — CMS ASP
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)

Total Part B spend
$114.1K
Claims
25
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$4,563.09
Where J2425 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #682 of 918
#677 GLYCOPYRROLATE(J1596... J1596 $128.4K #678 LINCOCIN* J2010 $125.5K #679 CYTAL, PER SQUARE CE... Q4166 $120.2K #680 MICAFUNGIN(J2248)* J2248 $119.6K #681 SINUVA J7402 $118.6K #682 KEPIVANCE J2425 $114.1K #683 FAMOTIDINE J1308 $112.6K #684 METHOTREXATE SODIUM* J9260 $111.6K #685 VINCASAR PFS* J9370 $111.3K #686 PROGENAMATRIX, PER S... Q4222 $110.1K #687 CEFAZOLIN SODIUM-DEX... J0690 $104.6K
Total claims — #884 of 918
#879 ELLENCE J9178 29 #880 BACLOFEN(J0476)* J0476 28 #881 ARGATROBAN-0.9% NACL... J0883 28 #882 MATRION 1 SQ CM** Q4201 26 #883 DAPTOMYCIN(J0877) J0877 25 #884 KEPIVANCE J2425 25 #885 HYMPAVZI PEN J7172 25 #886 ROMIDEPSIN J9318 24 #887 DIGOXIN* J1160 23 #888 NALOXONE HCL(J2312) J2312 23 #889 RIASTAP J7178 22

Full breakdown by period (1)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2025 (Q1-Q4) $114.1K — 25 — $4,563.09
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$32K
Medicare paid
$26.1K
Submitted services
927
Submitted charges
$110.3K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J2425 billing FAQ

What is HCPCS code J2425?
J2425 is a HCPCS Level II J-code used to bill Injection, palifermin, 50 micrograms under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J2425?
One unit of J2425 represents 50 MCG. Report the number of units equal to the dose administered divided by 50 MCG.
How many units of J2425 should I bill?
Divide the dose administered by the code's unit size (50 MCG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J2425?
The Medicare Part B payment limit is $38.690 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $37.916 per unit. Payment limits are revised quarterly.
Which NDCs bill under J2425?
2 NDCs currently map to J2425 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J2425 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.